Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer
(2017) In European Journal of Immunology 47(2). p.385-393- Abstract
Checkpoint blockade of CTLA-4 results in long-lasting survival benefits in metastatic cancer patients. However, patients treated with CTLA-4 blockade have suffered from immune-related adverse events, most likely due to the breadth of the induced T-cell activation. Here, we investigated the efficacy of a local low-dose anti-CTLA-4 administration for treatment of subcutaneous or orthotopic murine bladder 49 (MB49) bladder carcinoma in C57BL/6 mice. When MB49 tumors were grown s.c., peritumoral (p.t.) injection of anti-CTLA-4 treatment was equally effective as intravenous or s.c. (nontumor bearing flank) administration. Notably, p.t. injection was associated with lower circulating antibody levels and decreased IL-6 serum levels as compared... (More)
Checkpoint blockade of CTLA-4 results in long-lasting survival benefits in metastatic cancer patients. However, patients treated with CTLA-4 blockade have suffered from immune-related adverse events, most likely due to the breadth of the induced T-cell activation. Here, we investigated the efficacy of a local low-dose anti-CTLA-4 administration for treatment of subcutaneous or orthotopic murine bladder 49 (MB49) bladder carcinoma in C57BL/6 mice. When MB49 tumors were grown s.c., peritumoral (p.t.) injection of anti-CTLA-4 treatment was equally effective as intravenous or s.c. (nontumor bearing flank) administration. Notably, p.t. injection was associated with lower circulating antibody levels and decreased IL-6 serum levels as compared to systemic treatment. Ultrasound-guided intratumoral anti-CTLA-4 antibody treatment of orthotopically growing MB49 tumors resulted in tumor regression, with more than tenfold reduction in systemic antibody levels as compared to i.v. or s.c. administration, in line with the compartmentally restrained nature of the bladder. Local anti-CTLA-4 therapy in combination with anti-PD-1 therapy resulted in complete responses, superior to each therapy alone. In addition, p.t. anti-CTLA-4 therapy was potentiated by depletion of regulatory T cells. Our results demonstrate that local anti-CTLA-4 antibody therapy is equally effective as systemic administration, but reduces systemic antibody levels and cytokine release, and enhances the response to anti-PD1 therapy.
(Less)
- author
- van Hooren, Luuk ; Sandin, Linda C ; Moskalev, Igor ; Ellmark, Peter LU ; Dimberg, Anna ; Black, Peter ; Tötterman, Thomas H and Mangsbo, Sara M
- organization
- publishing date
- 2017-02
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Bladder cancer, Checkpoint inhibitors, CTLA-4, Immunotherapy, Local low-dose, MB49, PD-1
- in
- European Journal of Immunology
- volume
- 47
- issue
- 2
- pages
- 385 - 393
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- scopus:85006725021
- pmid:27873300
- wos:000394839800018
- ISSN
- 0014-2980
- DOI
- 10.1002/eji.201646583
- language
- English
- LU publication?
- yes
- id
- e149f8d5-9e5d-4d70-b20f-0ec51bba3d53
- date added to LUP
- 2017-02-01 07:29:31
- date last changed
- 2025-01-12 20:25:38
@article{e149f8d5-9e5d-4d70-b20f-0ec51bba3d53,
abstract = {{<p>Checkpoint blockade of CTLA-4 results in long-lasting survival benefits in metastatic cancer patients. However, patients treated with CTLA-4 blockade have suffered from immune-related adverse events, most likely due to the breadth of the induced T-cell activation. Here, we investigated the efficacy of a local low-dose anti-CTLA-4 administration for treatment of subcutaneous or orthotopic murine bladder 49 (MB49) bladder carcinoma in C57BL/6 mice. When MB49 tumors were grown s.c., peritumoral (p.t.) injection of anti-CTLA-4 treatment was equally effective as intravenous or s.c. (nontumor bearing flank) administration. Notably, p.t. injection was associated with lower circulating antibody levels and decreased IL-6 serum levels as compared to systemic treatment. Ultrasound-guided intratumoral anti-CTLA-4 antibody treatment of orthotopically growing MB49 tumors resulted in tumor regression, with more than tenfold reduction in systemic antibody levels as compared to i.v. or s.c. administration, in line with the compartmentally restrained nature of the bladder. Local anti-CTLA-4 therapy in combination with anti-PD-1 therapy resulted in complete responses, superior to each therapy alone. In addition, p.t. anti-CTLA-4 therapy was potentiated by depletion of regulatory T cells. Our results demonstrate that local anti-CTLA-4 antibody therapy is equally effective as systemic administration, but reduces systemic antibody levels and cytokine release, and enhances the response to anti-PD1 therapy.</p>}},
author = {{van Hooren, Luuk and Sandin, Linda C and Moskalev, Igor and Ellmark, Peter and Dimberg, Anna and Black, Peter and Tötterman, Thomas H and Mangsbo, Sara M}},
issn = {{0014-2980}},
keywords = {{Bladder cancer; Checkpoint inhibitors; CTLA-4; Immunotherapy; Local low-dose; MB49; PD-1}},
language = {{eng}},
number = {{2}},
pages = {{385--393}},
publisher = {{John Wiley & Sons Inc.}},
series = {{European Journal of Immunology}},
title = {{Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer}},
url = {{http://dx.doi.org/10.1002/eji.201646583}},
doi = {{10.1002/eji.201646583}},
volume = {{47}},
year = {{2017}},
}